ABBV Share Price Performance

US$207.86

19.86 (10.56%)

US$249.43

Fair Value

US$207.86

19.86 (10.56%)

16.7% undervalued

US$249.43

Fair Value

US$207.86

US$249.43

Thu, 23 Apr 26

Fair ValueUS$249.43

Share Pricen/a

ABBV Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value US$249.43 16.7% undervalued

Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025

278

About ABBV

Founded: 2012
Employees: 57000
CEO: Robert Michael
WebsiteView website: www.abbvie.com

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Recent ABBV News & Updates

Announcement • May 07

AbbVie Inc. Presents New Long-Term Data For Skyrizi And Rinvoq In Inflammatory Bowel Diseases

AbbVie announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2–5 in Chicago. AbbVie will present 18 abstracts, including real-world evidence and long-term findings for SKYRIZI (risankizumab-rzaa) and RINVOQ (upadacitinib) in Crohn's disease and ulcerative colitis. A 52-week follow-up of adults with moderately to severely active Crohn's disease treated with risankizumab from the ASPIRE-CD study showed rapid and sustained improvements in abdominal pain, bowel urgency and liquid/soft stools. Among patients with extraintestinal manifestations of arthritis and skin conditions, 25% and 46%, respectively, reported experiencing relief at Week 52. By Week 52, the use of corticosteroids decreased from 34% at baseline to 7%, and over-the-counter therapies had decreased from 72% at baseline to 49%. In an analysis of health-related quality of life and treatment satisfaction after initiating risankizumab in patients enrolled in the ASPIRE-CD study, 77% reported improvement in life enjoyment by Week 52. Patients had improved general wellbeing, including improved sexual health and improved work productivity and daily activity levels one year after starting risankizumab. Overall satisfaction with Crohn's disease treatments improved among all patients (from 50% at baseline to nearly 87% at Week 52), particularly patients who were still being treated with risankizumab at Week 52 (92% satisfaction). A real-world study of US claims data analyzed the switch rates over a 24-month period among patients with Crohn's disease initiating a new biologic therapy. It found the switch rate was 14% for risankizumab, compared with 21% for ustekinumab, 30% for vedolizumab, 33% for infliximab, and 36% for adalimumab. A retrospective analysis of US claims data found that among patients with Crohn's disease or ulcerative colitis treated with a biologic therapy, patients who were switched to upadacitinib had a 31% lower odds of hospitalization and 26% lower odds of emergency department visits than those who increased average weekly dose of the biologic therapy. Among patients with Perianal Fistulizing Crohn's disease, in two Phase 3 trials, those who responded to upadacitinib 45 mg were re-randomized to receive maintenance treatment with upadacitinib (15 mg or 30 mg) or placebo for 52 weeks. In this post-hoc analysis, upadacitinib-treated patients showed endoscopic improvements through 52 weeks, regardless of fistula response, as demonstrated by reductions in Simple Endoscopic Score for Crohn's disease. Majority of these patients were without an adequate response to anti-tumor necrosis factor therapy.

Recent updates

No updates

AbbVie Inc. Stock Price

ABBV Share Price Performance

ABBV Community Narratives

Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025

Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025

Trending Discussion

Recently Updated Narratives

ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution

Snowflake Analysis

AbbVie Inc. Key Details

About ABBV

Recent ABBV News & Updates

AbbVie Lifts Guidance After Q1 Beat With Immunology and Neuroscience Fueling Growth

AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing

AbbVie Inc. Presents New Long-Term Data For Skyrizi And Rinvoq In Inflammatory Bowel Diseases

Recent updates

AbbVie Inc. Competitors

Eli Lilly

Johnson & Johnson

Merck